Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in Chronic Myelomonocytic Leukemia
NCT01251627Phase 2Completed
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche
- Start
- Apr 2010
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in chronic myelomonocytic leukemia (CMML), sponsored by Fondazione Italiana Sindromi Mielodisplastiche. Primary endpoint: Activity of Decitabine at 24 months. Started Apr 2010; status: completed.
02
Drugs
decitabine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01251627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251627.